Address: Arzneimittel AG,Stadastraße 2-18, 61118 Bad Vilbel, Germany
Tel: 06101 603-0
Email: info@stada.de
Website: http://stada.com
STADA is an international company with more than 117 years experience and is dedicated to the development of generic drugs and biosimilars. Worldwide, STADA is represented in more than 30 countries in about 50 subsidiaries. Branded products such as Grippostad, Aqualor, Snup and Ladival are among the top sellers in their respective product categories.
The latest news from German pharma, including looming drug pricing reform, Boehringer Ingelheim’s EUR 640 million acquisition of a Kyowa Kirin autoimmune drug, and BioNTech’s updated revenue guidance. Also covered…
Pharmaceutical manufacturing is evolving into a strategic pillar of competitiveness, shaped by modular design, digital integration, and a growing focus on long-term efficiency. Bilfinger, through its Technology segment, is playing…
As China and the US attract an increasing share of commercial clinical trials, Europe is fighting to reclaim its spot as a global research leader. While Europe has world-class hospitals…
Once a little-known mRNA pioneer, BioNTech became a household name with its COVID-19 vaccine developed alongside Pfizer. But the German biotech is now pursuing an even bigger transformation — and…
A summary of some of the top stories coming out of Germany’s biopharma industry, including Bayer’s EMA win for its Eylea eye therapy; the oncology deal Merck KGaA has cut…
After February’s snap election that brought Friedrich Merz to power, a coalition between his conservative CDU/CSU bloc and the centre-left SPD has outlined an agreement this month that will serve…
While Europe has lost some of its global share of clinical trials to China and the US, it remains a clinical research stronghold. Three years into the Accelerating Clinical Trials…
Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. looks out over the choppy waters for life sciences venture capitalists in Europe over 2025. Three key initiatives stand to…
A roundup of the biggest stories coming out of Germany’s pharma industry, including Bayer’s biggest share price drop in 20 years; Fresenius Kabi’s biosimilar deal with SamChunDang Pharm; Halozyme Therapeutics’…
The latest news from German pharma, including why Merck KGaA is looking to life science M&A; positive outlooks for Bayer and STADA; BioNTech’s move into the AI lab assistant space…
Johannes Hauser, managing director of the German-Mexican Chamber of Commerce and Industry (AHK Mexico, or CAMEXA locally), shares the chamber’s functions, which include representing the German private sector in Mexico,…
A roundup of some of the biggest stories coming out of German pharma, including Merck’s better-than-expected Q1 earnings; Stada’s possible return to the stock market; CDMO Vetter’s expanded capacity in…
See our Cookie Privacy Policy Here
